Always there, always ready

Real people. Real time. Real commitment to supporting you.

test alt test alt

We’re here for you whenever…

  • Always accessible, 24/7/365, US–based support and service for medical, product, and technical needs

  • Urgent deliveries of INOmax® (nitric oxide) gas, for inhalation, cylinders and INOmax Delivery Systems, most often within 4 to 6 hours*

*Emergency deliveries are most often made within 4 to 6 hours, but may take up to 24 hours, depending on hospital location and/or circumstances.

test alt test alt

…wherever…

  • Regional Service Centers across the country to facilitate an emergency equipment response

  • Market-leading bedside and transport delivery systems to help provide seamless transport of neonates and equipment in and between facilities1

Based on December 2022 market share data.

test alt test alt

…and for whatever you need

  • A dependable inventory of INOmax Delivery Systems, INOmax cylinders, and consumables to support demand

  • Device-related trainings held live and virtually

Covers services included within your INOmax Total Care contract.

Watch this testimonial from a respiratory therapist to learn about their experience with INOmax Total Care service and support.

Play Video Button

Available across our portfolio of devices

Your institution will receive our full service and support offering no matter which contract option you choose. Our contract options work for all types of NICUs. Connect with a representative to find a contract option that works best for your institution.

Contact a representative to find out more

Contact a representative

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.

Reference: 1. Data on File – Ref-06557. Mallinckrodt Pharmaceuticals.

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

This website may identify third-party organizations and provide links to third-party websites or other third-party information (third-party content). The third-party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. All trademarks, service marks, and logos appearing on this website are the property of their respective owners. Any rights not expressly granted herein are reserved.

© 2023 Mallinckrodt. All rights reserved. US-2201223 11/23

© 2023 Mallinckrodt. All rights reserved. US-2300142 11/23

By viewing this site you agree to our Terms of Use. The product information provided in this site is intended only for residents of the United States. The product discussed herein may have different product labeling in different countries.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.